Blood Pressure Control, Drug Therapy, and Kidney Disease
暂无分享,去创建一个
T. Greene | R. Toto | B. Wilkening | L. Agodoa | E. Miller | J. Lash | G. Contreras | D. Cheek | M. Lipkowitz | D. Dowie | A. Ojo | George Junco | M. Sika
[1] Douglas G Altman,et al. Analysis and reporting of factorial trials: a systematic review. , 2003, JAMA.
[2] Tom Greene,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.
[3] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .
[4] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[5] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[6] Keith C. Norris,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.
[7] Teven,et al. EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .
[8] G. Bakris,et al. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. , 2000, Kidney international.
[9] G. Bakris,et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. , 1999, Kidney international.
[10] G. Remuzzi,et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). , 1998, Journal of the American Society of Nephrology : JASN.
[11] P. Whelton,et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. , 1997, JAMA.
[13] S. Leurgans,et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.
[14] F. Locatelli,et al. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .
[15] P. Whelton,et al. Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.
[16] F. Locatelli,et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.
[17] M. Epstein,et al. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. , 1994, Archives of internal medicine.
[18] A Fournier,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.
[19] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[20] R. Cesaris,et al. Effects of Atenolol and Enalapril on Kidney Function in Hypertensive Diabetic Patients , 1993, Journal of cardiovascular pharmacology.
[21] J. Westcott,et al. Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. , 1991, The Journal of clinical investigation.
[22] E. Lewis,et al. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. , 1987, The American journal of physiology.
[23] B. Brenner,et al. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. , 1986, The Journal of clinical investigation.
[24] M. Epstein,et al. Effects of calcium antagonists on renal hemodynamics. , 1985, The American journal of physiology.
[25] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.